2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
170
Neoplasm Metastasis
13
Prostatic Neoplasms, Castration-Resistant
11
Metastatic Castration-resistant Prostate Cancer
7
Neoplasms
6
Metastatic Castration Resistant Prostate Cancer
6
Breast Neoplasms
6
Prostate Cancer Metastatic
4
Metastatic Castration-Resistant Prostate Cancer
4
Urogenital Neoplasms
3
Genital Neoplasms, Male
3
Prostatic Diseases
2
Neoplasms by Site
2
Metastatic Castration-resistant Prostate Cancer (mCRPC)
2
Genital Diseases, Male
2
Castration-resistant Prostate Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Adenocarcinoma
2
Urinary Bladder Neoplasms
1
Stage II Prostate Adenocarcinoma
1
Sleep Initiation and Maintenance Disorders
1
Salivary Glands Tumors
1
Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone
1
Prostate Adenocarcinoma
1
Pharmacogenetic Study
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Oligometastatic Prostate Carcinoma
1
Newly Diagnosed Oligometastatic Prostate Cancer
1
Neoadjuvant Therapy
1
Interventions
Androgen Antagonists
3
darolutamide
2
Docetaxel
2
relugolix
1
niraparib
1
Prednisone
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
×
Abiraterone Acetate
×
Clear all
NCT06392841
2026-04-08
HARMONY
Hoosier Cancer Research Network
Phase 2
Withdrawn